Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients.
BACKGROUND
Variceal bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first bleeding or rebleeding is mandatory.


OBJECTIVE
To provide an overview of the current knowledge on the best evidence-based therapeutic options to prevent first or recurrent bleeding from oesophageal varices in patients with cirrhosis.


METHODS
For the preparation of this narrative review, we sought to analyse randomized controlled trials that examined the efficacy and side effects of pharmacological or endoscopic therapy for the primary and secondary prophylaxis of oesophageal variceal bleeding.


RESULTS
Endoscopic band ligation (EBL) and nonselective beta-blockers are both effective in preventing first bleeding. Until more long-term data are available, nonselective beta-blockers should be the first treatment option because of less severe side effects. EBL is an alternative when beta-blockers are contraindicated or not tolerated. Patient preference may also be considered. For prevention of rebleeding, nonselective beta-blockers (preferably in association with isosorbide-5-mononitrate) or EBL are both effective and good alternative treatments. A combination of both treatments may be the best alternative.


CONCLUSIONS
A great improvement in the prevention of variceal bleeding has emerged over the last years. However, further therapeutic options that combine higher efficacy, better tolerance and fewer side effects are needed.
Garcia-Pagan
J C
JC
Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain. jcgarcia@clinic.ub.es
De Gottardi
A
A
Bosch
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006975:Hypertension, Portal / Q000628:therapy*; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008026:Ligation; D008103:Liver Cirrhosis / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D015911:Sclerotherapy; D055502:Secondary Prevention; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate